Khalid M. Kamal, M.Pharm, Ph.D.

My primary areas of research interests include health outcomes research with particular emphasis on improving the quality of pharmaceutical care services and the cost-effective use of drugs in the healthcare system. 

My research agenda is divided into three broad research fronts: conducting pharmacoeconomics evaluations, assessing quality of care in a primary care setting using electronic medical records (EMRs), and studying the impact of diseases on healthcare cost and resource utilization.  

Graduate Courses

• Pharmacoeconomic Evaluations (GPSC 590) - 3 Crs. (Spring; 100%)
• Patient-Reported Health Outcomes (GPSC 591) - 3 Crs. (Fall; 100%)
• Research Methods in Pharmacy Administration (GPSC 589) - 3 Crs. (Fall; Team Taught - 40%; Course master)

Undergraduate Courses

• The American Healthcare System (PHBA 410) - 2 Crs. (Spring; Team Taught - 30%; Course master)
• Pharmacy Practice V (PHPR 447) - 3 Crs. (Fall; Team Taught - 34%)
• Drug Literature Evaluation (PHPR 448-71) - 2 Crs. (Fall; Team Taught - 30%)
• International Pharmacy - Japan (PHBA 428) - 3 Crs. ( Summer (100%)

GRANTS/CONTRACTS - 2006 to present

Economic and humanistic outcomes   in patients with advanced renal cell carcinoma
$7,000 (PI) Arnold Consultancy Technology, LLC 2010      
                                                            
Examining the consequences of multiple sclerosis from a patient perspective. 
$20,268.75 (PI) Novartis Pharmaceuticals 2010

Non-medical switching between different ARBs on continuity of care and BP control.
$50,556.25 (PI) Novartis Pharmaceuticals 2009-11

Quality improvement in physician process and patient outcomes in diabetes care.   
$5,000 (PI) Duquesne University Presidential Scholarship Award 2008-2009

Pharmacoeconomic evaluation of TNF inhibitors in AS.
$9,887 (PI) Duquesne University Faculty Development Fund 2007-2010                                                    
                                                                                    
Consequences of pharmacy benefits design.
$22,696.33 (Co-I) Novartis Pharmaceuticals  2006-2007 

Content analysis of FDA warning letters to manufacturers.
$7,389.37 (Co-I) Novartis Pharmaceuticals 2006-2007

PUBLICATIONs' 2006 to present

Mylan School of Pharmacy's Faculty Award for outstanding contributions in teaching, service, and scholarship, 2010.
Nominated by Duquesne University Mylan School of Pharmacy for Duquesne University President's Faculty Award for Excellence in Scholarship: 2011 and 2010.

Dudash K, Kamal KM. Use of tumor necrosis factor inhibitors in Ankylosing Spondylitis:  A cost-effectiveness analysis and budget impact analysis. Selected as the best paper in the Student/Fellows/Residents presentation category at the annual meeting of Academy of Managed Care Pharmacy (AMCP), San Diego, April 2010.

Khanna R, Kamal KM, Smith M. Utilization and costs of drugs and office services among recipients of Medicaid with rheumatoid arthritis with versus without comorbid depression. Association of Rheumatology Health Professionals Graduate Student Award, 2006.

Graduate Research Award, School of Pharmacy, West Virginia University, 2001-02.
All India Council of Technical Education Junior Research Fellowship, 1994-96.

International Society for Pharmacoeconomics & Outcomes Research (ISPOR) - 2000 - Present

Academy of Managed Care Pharmacy (AMCP) - 2012

American Association of Colleges of Pharmacy (AACP) - 2006 - Present

Association of Rheumatology Health Professionals (ARHP) - 2006, 2007

Society for Medical Decision Making (SMDM) - 2006, 2007

Rho Chi Honor Society - 2000 - Present